Research at Oslo University Hospital

 

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

 

Latest news

OUH researchers publish groundbreaking computer tools for cell biology research in Nature Methods

 

A group at the Department of Immunology at OUH has developed software tools that help solving one of the biggest challenges in large-scale protein analysis, or proteomics. In an article published in prestigious Nature Methods (journal impact factor 32.1) they show that Microsoft Excel can be applied to align large datasets from multiple studies and obtain a better picture of how cells are wired.

 
 

POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis

 
Ragnhild A. Lothe and Arild Nesbakken
Ragnhild A. Lothe and Arild Nesbakken

A multicentre biomarker study, including data from the research teams of professors Ragnhild A. Lothe and Arild Nesbakken at the K.G.Jebsen Colorectal Cancer Research Centre, OUH, was recently published in Lancet Gastroenterology & Hepatology.
A small subgroup of patients with exceptionally mutated (ultramutated) cancers caused by mutations that impair DNA polymerase epsilon (POLE) proofreading are shown to have excellent prognosis.

 
 

Clinical Cancer Research highlights biomarker paper from Lyng’s group

 
Christina Sæten Fjeldbo (first author)
Christina Sæten Fjeldbo (first author)

Molecular targeting of tumor hypoxia is a promising strategy for improving the radiotherapy of cervical cancer. A biomarker for classifying patients according to hypoxia is, however, lacking and is an important requirement for reliable drug evaluation and to avoid added toxicity to patients with no expected benefit.
In a study published in Clinical Cancer Research (journal impact factor 8.7), postdoc Christina S. Fjeldbo (photo) in Lyng’s group and colleagues at Oslo University Hospital and Aarhus University Hospital present a hypoxia classifier that is reflected in diagnostic DCE-MR images and based on the expression level of six genes in a biopsy.

 
 

Jonathan M. Irish speaks at CCB seminar August 31st at 12:00:

Decoding human tumor microenvironments and healthy tissues using high dimensional single cell mass cytometry

 
Jonathan M. Irish
Jonathan M. Irish

The CCB seminar Wednesday 31st of August will be held by Jonathan M. Irish, Ph.D., Assistant Professor at the Department of Cancer Biology and the Department of Pathology, Microbiology, & Immunology, Vanderbilt University, Nashville, Tennessee.
Title of his talk: Decoding human tumor microenvironments and healthy tissues using high dimensional single cell mass cytometry
Time and place: Wednesday the 31st of August at 12:00 hrs, Auditorium, New research building, Institute for Cancer Research, Montebello.
Refreshments are served in the lobby after the seminar

 
 

The Norwegian Cancer Genomics Consortium participates in international study of gene variants predisposing for cancer development.

 
Ola Myklebost
Ola Myklebost

Norwegian Cancer Genomics Consortium (NCGC) consists of clinicians and specialised cancer research groups, situated at the Norwegian University Hospitals, and is led by professor Ola Myklebost (photo) from the Department of Tumor Biology at Oslo University Hospital.
The NCGC participates in an international study of gene variants predisposing for cancer development. Findings from the study has recently been published in Lancet Oncology (journal impact factor 24.69). The article - entitled "Monogenic and polygenic determinants of sarcoma risk: an international genetic study" has also got an editorial comment: "Are sarcomas hereditary?".

 
 

The Norwegian Cancer Society calls attention to collaborative study on relevance of genetic heterogeneity

 
Anita Sveen is heavily involved in the study (photo Terje Heiestad)
Anita Sveen is heavily involved in the study (photo Terje Heiestad)

The Norwegian Cancer Society has recently presented a research project on their home page where researchers from Oslo and Bergen have performed genetic analyses on cancer cells that have spread from the gut to the liver. The results show that the degree of genetic heterogenenity between the metastases to the liver may reveal important prognostic information.. The study led by Ragnhild A. Lothe from the Department of Moleceular Oncology at OUS and Per Eystein Lønning from Haukeland University Hospital.

 
 

Clinical relevance of genetic heterogeneity among distinct liver metastatic deposits identified in patients with colorectal cancer

 
Anita Sveen (first author)
Anita Sveen (first author)

In this collaborative study with Dept Oncology, Haukeland University Hospital and Dept Computer Science, University of Oslo, scientist Anita Sveen (photo) and colleagues in the Lothe group show that patients with a low level of heterogeneity, based on DNA copy number analyses of multiple metastases per patient, have a 4.6X and 3.6X longer three-year progression free and overall survival rate than patients with a high heterogeneity level.

 
 

Call for applications 2017

Annuncement of research funding from South-East Norway regional health authority for 2017

 

The South-Eastern Norway Regional Health Authority hereby announces a call for applications for research projects and research activities starting in 2017.

The total funding available for this call is approximately 100 million Norwegian kroner.

Application deadline is Tuesday, September 6th 2016 kl. 16:00.

 
 

H.M. the King's Gold Medal to Marina Vietri

 

Marina Vietri from Institute for Cancer Research and Centre for Cancer Biomedicine is awarded H.M. the King's Gold Medal for best thesis of the Faculty of Medicine.

She will receive the medal at the annual celebration of the University of Oslo in the University Aula on 2nd September.

 
 

Oslo University Hospital has awarded 6 excellent articles for the second half-year of 2015

 
Award winners of excellent article prize
Award winners of excellent article prize

In order to stimulate excellent research and draw attention to the hospital's extensive research activity, Oslo University Hospital reward outstanding publications regularly.

Six research groups were awarded for their excellent papers published during the second half-year of 2015 during a ceremony June 17th. Each group was given NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.

The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.